A Clinical Review of the Treatment of Diabetic Ulcers, Pressure Ulcers and Venous Stasis Ulcers in Human Subjects Using Silver Sol Gel While Residing in a Geriatric Health Care Facility

By

Gordon Pedersen, Ph.D.

Abstract

Diabetic ulcers, pressure ulcers and venous stasis ulcers were treated with Silver Sol Gel in conjunction with Advanced Healing Systems Formulary process that includes new technologies that are in combination with the best practices available in wound care resulting in remarkable recoveries. The weekly photographic and empirical quantification of the healing processes are recorded in this study. The weekly improvements seen in very difficult cases illustrate the broad-spectrum abilities of Silver Sol Gel. Diabetics suffer from hormone changes, reduced blood flow to extremities and wounds that heal very slowly if at all. These diabetic wounds remain open for long periods of time and are susceptible to bacterial, viral and fungal infection. Diabetic wounds have been shown to be polymicrobial and difficult to treat.

Silver Sol Gel was used to treat the diabetic ulcer, pressure ulcers and venous stasis ulcers of patients being treated in outpatient and long term care facilities where data was collected by Advanced Health Systems (AHS). The resident doctors and nurses applied Silver Sol Gel to these types of wound and recorded the size of wound, depth of wound, area of wound and time to closure. In addition photos were taken and recorded on a weekly basis.

In this study Silver Sol Gel in combination with best practices reduced the size of the wound, the depth of the wound and area of wounds found in diabetic ulcers, pressure ulcers and venous stasis ulcers, and accomplished complete wound closure and healing in 5 to 12 weeks. The improvements seen in the weekly photographs visually depict three remarkable recoveries using Silver Sol. The remarkable recoveries can be explained by the fact that silver sol completely destroys bacteria, viruses and fungi. By reducing the polymicrobial infections sustained in diabetic wounds, the associative swelling was reduced, thus allowing better circulation immune access and improved wound healing.
Literature Review

Type 1 Diabetes is a chronic disease that occurs when the beta cells of the pancreas are not able to produce enough insulin to properly control blood sugar levels (3). In the absence of insulin, glycogenesis and glycolysis are adversely affected (4). It is currently thought that insulin acts primarily at the cell membrane facilitating transport of glucose into the cell (4). Symptoms of diabetes appear or are aggravated through the following causes: Genetics, infections, pancreas dysfunction and lack of exercise and poor diet (4).

Diabetic Ulcers are also called Diabetic Bullae, Skin Ulcers & Diabetes, and Bullosis Diabeticorum. An ulcer can apply to any open wound or sore, but a diabetic ulcer usually involves a serious condition usually found in the extremities or back and is always associated with a person who has diabetes.

People with diabetes are at increased risk of developing pressure sores (bed sores) which present with a breakdown in the skin and underlying tissues due to prolonged pressure such as laying in bed for extended periods of time.

Diabetes may produce numerous complications that can lead to problems throughout all systems of the body. Especially serious and debilitating problems include open sores that don’t heal. These open sores or ulcers are caused by the decrease in circulation, infections and changes in blood vessels due to symptoms of diabetes. Many patients have diabetic ulcers that become infected before they are discovered due to neuropathy caused by diabetes.

Typically diabetic ulcers consist of more than one type of bacterium (called Polymicrobial ulcers). It is common for 4 to 6 different bacteria to be present in the diabetic wound. The most common infective agents include staph and streptococcus although pseudomonas and candida (a yeast) may also co-contaminate these diabetic ulcers (1). Since Diabetics have vaso-constricted arteries the amount of blood flow is compromised which results in a decrease in immune competency, blood flow, oxygen and nutrients necessary for the healing process to proceed at a normal rate. These patients may develop minor wounds that don’t close or heal for years, due to the fact that they are open and become infected with numerous types of bacteria and yeast. Once infected the diabetic patient has a much more difficult time in closing and healing the wound compared to normal heal rates. Over time, infected ulcers may cause enough tissue damage to require surgical intervention or amputation. For this reason diabetes is the number one cause of foot amputations in America (2).

This study focuses on human diabetic subjects that have developed diabetic ulcers and were treated with the anti-microbial, antifungal and antiviral agent Silver Sol. Silver Sol gel was applied topically to diabetic wounds and found to destroy the cause of infection and help improve wound healing in diabetic patients residing in a geriatric health care facility.
Silver Sol gel has been demonstrated to completely destroy bacteria and yeast (5). It improves healing outcomes from MRSA (7), and has been shown to promote faster and less painful healing times (7). For these and many more reasons Silver Sol was selected to treat infected wounds in the diabetic patients.

**Materials and Methods**

Three case studies were selected for diabetes and open wounds based on the quality of their photographic recordings of Silver Sol and best practices treatment. Health care professionals treated each patient with Silver Sol Gel, best practices and photographed their progress.

These photographs illustrate routine but significant improvements in wound closure and healing that regularly take place at this facility. All patients were under the care of properly licensed physicians and nurses. Silver Sol Gel was applied once or twice daily depending on the doctor’s recommendations.

Wounds were measured for length depth and area and records recorded weekly. Photographs were taken before silver sol treatment was initiated and then every week afterwards.

Size of wound, area of wound, time to closure and photographs of before, during and after treatment with silver sol were recorded with the intent that doctors from other facilities could observe these results and compare similar treatments and outcomes.

The Silver Sol Gel (24 ppm), contains purified water, pure silver and the gelling agents carbomer/TEA, and was obtained from American Biotech Labs, Alpine Utah.

**Results**

Three cases were selected to illustrate diabetic ulcers, pressure ulcers and venous stasis ulcers. To date AHS has treated hundreds of these types of patients and have a remarkable record of healing using the silver sol product.

**Subject #1 Diabetic Ulcer.**

The diabetic patient presented with a foot ulcer, was treated with silver sol gel twice a day and achieved total recovery in 5 weeks.
<table>
<thead>
<tr>
<th>Week</th>
<th>Date</th>
<th>Length</th>
<th>Width</th>
<th>Depth</th>
<th>Volume</th>
<th>% Closure</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>04/27/2008</td>
<td>1.5</td>
<td>1</td>
<td>0.1</td>
<td>0.050</td>
<td>0</td>
<td>PEMF, AHS Silver Sol</td>
</tr>
<tr>
<td>1</td>
<td>05/05/2008</td>
<td>1.3</td>
<td>0.6</td>
<td>0.1</td>
<td>0.078</td>
<td>48.00</td>
<td>PEMF, AHS Silver Sol</td>
</tr>
<tr>
<td>2</td>
<td>05/12/2008</td>
<td>1.1</td>
<td>0.5</td>
<td>0.1</td>
<td>0.050</td>
<td>63.33</td>
<td>PEMF, AHS Silver Sol</td>
</tr>
<tr>
<td>3</td>
<td>05/19/2008</td>
<td>0.7</td>
<td>0.2</td>
<td>0.1</td>
<td>0.014</td>
<td>96.67</td>
<td>PEMF, AHS Silver Sol</td>
</tr>
<tr>
<td>4</td>
<td>06/06/2008</td>
<td>0.5</td>
<td>0.1</td>
<td>0.1</td>
<td>0.003</td>
<td>98.00</td>
<td>PEMF, AHS Silver Sol</td>
</tr>
<tr>
<td>5</td>
<td>06/13/2008</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100.00</td>
<td>PEMF, AHS Silver Sol</td>
</tr>
</tbody>
</table>

**Volume**

**% Closure**

**Date**

**Wound Image**

04/27/2008
Subject #2 Pressure Ulcer

The patient presented with a pressure ulcer was treated with silver sol gel twice daily and achieved wound closure and complete healing in 12 weeks.

<table>
<thead>
<tr>
<th>Week</th>
<th>Date</th>
<th>Length</th>
<th>Width</th>
<th>Depth</th>
<th>Volume</th>
<th>% Closure</th>
<th>Formulary</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>11/19/2008</td>
<td>13.8</td>
<td>3.7</td>
<td>2.5</td>
<td>124.8750</td>
<td>0</td>
<td>PEMF AHS Silver Sol</td>
<td>undermining 8.7cm at 11 o'clock to 2 o'clock. Previous blood clot passed making undermining deeper. Wound bed looks clean. AHB amnestic WCC</td>
</tr>
<tr>
<td>1</td>
<td>11/20/2008</td>
<td>13.4</td>
<td>3.7</td>
<td>2.5</td>
<td>122.9500</td>
<td>0.74</td>
<td>PEMF AHS Silver Sol</td>
<td>undermining at 11 o'clock 8.9cm, 12 o'clock 8.8cm, 1 o'clock 8.5cm. No photo taken. Measurements provided by floor nurse.</td>
</tr>
<tr>
<td>2</td>
<td>11/25/2008</td>
<td>13.6</td>
<td>4.8</td>
<td>2</td>
<td>132.5900</td>
<td>-4.05</td>
<td>PEMF AHS Silver Sol</td>
<td>undermining at 11 o'clock 7.4 cm, 12 o'clock 4.1cm, 1 o'clock 4.0 cm. Patient combative no photo taken.</td>
</tr>
<tr>
<td>3</td>
<td>12/04/2008</td>
<td>14.2</td>
<td>4.1</td>
<td>0.1</td>
<td>5.8200</td>
<td>95.34</td>
<td>PEMF AHS Silver Sol</td>
<td>undermining 11 o'clock measures 5.5 cm 12 o'clock measures 1.8 cm. Wound is healing.</td>
</tr>
<tr>
<td>4</td>
<td>12/11/2008</td>
<td>15.2</td>
<td>4.5</td>
<td>0.2</td>
<td>13.6800</td>
<td>89.05</td>
<td>PEMF AHS Silver Sol</td>
<td>undermining at 10:00 o'clock measures 7.7 cm, undermining at 11:00 o'clock measures 6.8 cm, 12:00 measure 2.8 cm. Wound is clean and pink in color with areas of granulation. Wound edges are attached and defined. Slight amount of serous serosanguineous drainage, no odor.</td>
</tr>
<tr>
<td>5</td>
<td>12/18/2008</td>
<td>15.2</td>
<td>4.3</td>
<td>0.2</td>
<td>13.0720</td>
<td>86.53</td>
<td>PEMF AHS Silver Sol</td>
<td>undermining is resolved, small amount of serosanguineous drainage present. No odor. Tissue is firm. No infections. 100% red glistening tissue. Epithelialization present at wound edges. Surrounding skin intact. No indications of infection. No pinprick. Current bx PEMF silver and visual lens eye test with ABO pad. AHB amnestic WCC</td>
</tr>
<tr>
<td>6</td>
<td>01/09/2009</td>
<td>12</td>
<td>4.1</td>
<td>0.1</td>
<td>4.9200</td>
<td>96.06</td>
<td>PEMF AHS Silver Sol</td>
<td>Scant amount of serosanguineous drainage. No odor. Wound tissue firmly adherent. 100% red glistening tissue. Wound bed is filling in nicely. Epithelialization tissue present. Surrounding tissue present. No indications of infection. No pinprick. No changes to bx. AHB amnestic WCC</td>
</tr>
<tr>
<td>7</td>
<td>01/15/2009</td>
<td>8.4</td>
<td>2.8</td>
<td>0.1</td>
<td>2.4300</td>
<td>98.05</td>
<td>PEMF AHS Silver Sol</td>
<td>Wound bed is granulating and filling in toward closure.</td>
</tr>
<tr>
<td>9</td>
<td>01/20/2009</td>
<td>6</td>
<td>1.3</td>
<td>0.1</td>
<td>0.8000</td>
<td>95.35</td>
<td>PEMF AHS Silver Sol</td>
<td>Wound bed is granulating and filling in toward closure.</td>
</tr>
<tr>
<td>10</td>
<td>02/05/2009</td>
<td>6</td>
<td>1.5</td>
<td>0.1</td>
<td>0.9000</td>
<td>95.28</td>
<td>PEMF AHS Silver Sol</td>
<td>Wound bed is granulating and filling in toward closure.</td>
</tr>
<tr>
<td>11</td>
<td>02/24/2009</td>
<td>6</td>
<td>0.7</td>
<td>0.1</td>
<td>0.0700</td>
<td>92.64</td>
<td>PEMF AHS Silver Sol</td>
<td>Wound bed 100% red glistening tissue. Wound edges are intact.</td>
</tr>
<tr>
<td>12</td>
<td>03/12/2009</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100.00</td>
<td></td>
<td>PEMF AHS Silver Sol</td>
<td>Wound resolved. AHB amnestic WCC</td>
</tr>
</tbody>
</table>
Subject #3 Venous Stasis Ulcer

Patient presented with venous stasis ulcer was treated with silver sol and achieved total wound closure and healing in 8 weeks.
Conclusions

Silver Sol has been shown to completely destroy the bacteria viruses and yeast in vitro and in vivo (8). This is extremely important to the diabetic patient because their wounds typically consist of multiple bacteria and yeast. Silver Sol reduces the inflammation and tissue damage caused by bacteria, viruses and yeast thus reducing the infections that impede normal circulation, blood flow, immune function and healing.

Silver Sol Gel significantly reduced the infection in diabetic wounds, as measured by size of wound, time to closure and reduction of infection.

Table 4
Summary of Wound Healing

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Size of wound</th>
<th>Percent wound closure (weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>wk 3</td>
</tr>
<tr>
<td>Diabetic Ulcer</td>
<td>1.5in X 3.6 in</td>
<td>84</td>
</tr>
<tr>
<td>Venous Stasis Ulcer</td>
<td>5.3 in X 5.1 in</td>
<td>83</td>
</tr>
<tr>
<td>Pressure Ulcer</td>
<td>13.6 in X 5.7 in</td>
<td>75</td>
</tr>
</tbody>
</table>

Table 4 illustrates the size of the wounds and the time to close these wounds. In all cases the wounds closed 75-84 percent within the first three weeks. The time it took for total wound closure was between 5-12 weeks with the larger wounds taking longer to close. It is remarkable that Silver Sol Gel helps promote complete infection free healing while assisting the immune system in closing wounds.

Ulcers in the diabetic patient can be polymicrobial and thus present a difficult problem is selecting a drug that is effective against numerous pathogens. Since there is no drug that has activity against bacteria, viruses and fungi, multiple drugs must be considered and many side effects controlled. Silver Sol has demonstrated the ability to destroy bacteria, viruses and fungi (broad spectrum of activity), making it a very desirable choice against the pathogens causing diabetic ulcers or any open wound. Silver Sol gel has been demonstrated to be an antimicrobial wound disinfectant, provide a moist protective barrier from pathogens, is water soluble, has been shown to reduce inflammation and stimulate stem cell activity. It contains no alcohol so it doesn’t cause any discomfort or burning sensation when applied to the wound. It contains no grease which would cause maceration of the wound. It allows the wound to breathe and heal at the same time it kills bacteria and yeast.

Wounds that would not previously heal were healed. No patients complained. There were no painful side effects.

This study demonstrates remarkable anti-microbial activity against polymicrobial diabetic wounds. By removing the infecting pathogens and helping support immune function,
silver sol promotes improved wound healing, which is of utmost significance in the diabetic patient. The diabetic patient who uses Silver Sol as recommended in this study should expect to see benefits in the first three days with continuous improvement until all the pathogens are killed and the wound completely heals (in 5-12 weeks). This healing appears to be three times faster than similar treatments that do not contain silver sol. This can be supported by numerous wound healing studies which found the use of Silver Sol gel (applied twice daily) to result in three times faster wound healing as determined by time to wound closure (1, 5, 7).

Daily use of silver sol is recommended for preventive treatment against bacteria, viruses and fungi, and has been reported to improve naturally occurring stem cell activity (6) thus assisting the diabetic patient in multiple ways yielding remarkable broad spectrum recoveries not previously produced in diabetic subjects.

In this study Silver Sol Gel reduced the size of the wound, the depth of the wound and area of wounds found in diabetic ulcers, pressure ulcers and venous stasis ulcers, and accomplished this complete wound closure and healing in 5 to 12 weeks. The improvements seen in the weekly photographs visually depict three remarkable recoveries using Silver Sol Gel. The remarkable recoveries can be explained by the fact that Silver Sol completely destroys bacteria, viruses and fungi. By reducing the polymicrobial infections sustained in diabetic wounds, the associative swelling was reduced, thus promoting better circulation, immune access and improved wound healing.

References


